May 29, 2020

 

Securities and Exchange Commission

100 F Street, N.E.

 

Amendment Number 1 to Registration Statement on Form S-1

Filed January 8, 2019

Registration No. 333- 229146 (the “Registration Statement”)

Ordered Effective February 11, 2019

 

Ladies and Gentlemen:

 

Pursuant to Rule 477 under the Securities Act of 1933, as amended, the undersigned issuer hereby requests that the above captioned Registration Statement, which was ordered effective on February 11, 2019, be withdrawn.  As adjusted for a subsequent 1,000 for 1 reverse stock split, 15,390 shares were sold under the Registration Statement and 65,860 shares remain unsold. The issuer is withdrawing the Registration Statement because the issuer does not intend to sell any further shares under the Registration Statement

 

Very truly yours,

Endonovo Therapeutics, Inc.

 

By: /s/ Alan Collier, CEO  
  Alan Collier, CEO  

 

Endonovo Therapeutics, Inc., 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367 www.endonovo.com

 

   

 

Endonovo Therapeutics (PK) (USOTC:ENDV)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Endonovo Therapeutics (PK).
Endonovo Therapeutics (PK) (USOTC:ENDV)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Endonovo Therapeutics (PK).